Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
Details : Through acquisition, Oragenics gained Odyssey’s assets, including drug candidates ONP-002 for mild traumatic brain injury and Niemann-Pick Disease Type C, alongside its nasal delivery device.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Recipient : Syneos Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. It crosses BBB & activates gene response leading to the production of proteins that reduce inflammation, oxidative str...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
November 16, 2023
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Recipient : Syneos Health
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Details : Through the agreement, Oragenics acquire Odyssey’s assets including drug candidates, ONP-002 for treating mild traumatic brain injury, and for treating Niemann Pick Disease Type C, as well as Odyssey’s proprietary powder formulation and its nasal del...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
October 05, 2023
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Oragenics
Deal Size : $1.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
Details : Oximes-based drug formulation is administered into the upper chamber of the nasal cavity using intranasal device. This helps antidote to cross the blood-brain barrier and spread throughout the brain quickly to reverse the harmful effects of the nerve gas...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
Details : No severe adverse events were noted as PRV-002 was well-tolerated for all cohorts. No delays were instituted between cohorts. Vital signs, EKG readings, sleep patterns and breathing function were all normal through the entirety of the study.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 28, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion), has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurostero...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroid, also reduces behavioral pathology associated with brain injury symptoms.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
July 12, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health Completes Safety Evaluation of Cohort II for Concussion Drug
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion).In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroi...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug
Details : PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion), In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurostero...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : PRV-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
